[go: up one dir, main page]

WO2008068621A3 - Produit de combinaison - Google Patents

Produit de combinaison Download PDF

Info

Publication number
WO2008068621A3
WO2008068621A3 PCT/IB2007/004299 IB2007004299W WO2008068621A3 WO 2008068621 A3 WO2008068621 A3 WO 2008068621A3 IB 2007004299 W IB2007004299 W IB 2007004299W WO 2008068621 A3 WO2008068621 A3 WO 2008068621A3
Authority
WO
WIPO (PCT)
Prior art keywords
gamma
combination product
ido inhibitor
tumor targeted
targeted ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/004299
Other languages
English (en)
Other versions
WO2008068621A2 (fr
Inventor
Angelo Corti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGC Biologics SpA
Original Assignee
MolMed SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MolMed SpA filed Critical MolMed SpA
Publication of WO2008068621A2 publication Critical patent/WO2008068621A2/fr
Publication of WO2008068621A3 publication Critical patent/WO2008068621A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un produit pharmaceutique qui comporte, en combinaison, (i) un inhibiteur de l'indoléamine 2,3-dioxygénase (IDO) et (ii) un produit de conjugaison de IFNγ et une fraction de ciblage (TM) ou un polynucléotide codant pour celui-ci.
PCT/IB2007/004299 2006-12-05 2007-12-05 Produit de combinaison Ceased WO2008068621A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0624308A GB0624308D0 (en) 2006-12-05 2006-12-05 Combination product
GB0624308.3 2006-12-05

Publications (2)

Publication Number Publication Date
WO2008068621A2 WO2008068621A2 (fr) 2008-06-12
WO2008068621A3 true WO2008068621A3 (fr) 2008-07-31

Family

ID=37711599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004299 Ceased WO2008068621A2 (fr) 2006-12-05 2007-12-05 Produit de combinaison

Country Status (2)

Country Link
GB (1) GB0624308D0 (fr)
WO (1) WO2008068621A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343081A1 (fr) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Analogues d'interféron
SG11201608708WA (en) 2014-05-15 2016-11-29 Iteos Therapeutics Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
WO2016147144A1 (fr) 2015-03-17 2016-09-22 Pfizer Inc. Nouveaux dérivés substitués par un 2-indole, compositions pharmaceutiques et leurs procédés d'utilisation
WO2016181349A1 (fr) * 2015-05-14 2016-11-17 Pfizer Inc. Combinaisons comprenant un inhibiteur d'ido1 de type pyrrolidine-2,5-dione et un anticorps
CN116196426A (zh) 2015-07-16 2023-06-02 百欧肯治疗有限公司 治疗癌症的组合物及方法
CA2994917A1 (fr) 2015-08-10 2017-02-16 Pfizer Inc. Derives substitues par un 3-indole, compositions pharmaceutiques et leurs procedes d'utilisation
WO2017080934A1 (fr) * 2015-11-09 2017-05-18 F. Hoffmann-La Roche Ag Essai de criblage permettant d'identifier des modulateurs de id01 et/ou de tdo
CN106075453A (zh) * 2016-07-12 2016-11-09 中国医学科学院基础医学研究所 一种抗肿瘤药物制剂组合
AU2018380409A1 (en) * 2017-12-08 2020-06-25 Chromocell Corporation Tryptophan derivatives as sweeteners
US20220256900A1 (en) * 2019-06-12 2022-08-18 Corn Products Development, Inc. Compositions with sugar like characteristics
EP3882257A1 (fr) * 2020-03-20 2021-09-22 Ospedale San Raffaele S.r.l. Conjugués ngr et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067633A2 (fr) * 2004-12-23 2006-06-29 Molmed Spa Produit de conjugaison

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067633A2 (fr) * 2004-12-23 2006-06-29 Molmed Spa Produit de conjugaison

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADIKARI S B ET AL: "Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY NOV 2004, vol. 138, no. 2, November 2004 (2004-11-01), pages 230 - 236, XP002481684, ISSN: 0009-9104 *
BRANDACHER G ET AL: "Antitumoral activity of interferon-[gamma] involved in impaired immune function in cancer patients", CURRENT DRUG METABOLISM 200608 NL, vol. 7, no. 6, August 2006 (2006-08-01), pages 599 - 612, XP009100735, ISSN: 1389-2002 *
CURNIS FLAVIO ET AL: "Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.", CANCER RESEARCH 1 APR 2005, vol. 65, no. 7, 1 April 2005 (2005-04-01), pages 2906 - 2913, XP002481685, ISSN: 0008-5472 *
MULLER ALEXANDER J ET AL: "Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy", NATURE MEDICINE, vol. 11, no. 3, March 2005 (2005-03-01), pages 312 - 319, XP002481687, ISSN: 1078-8956 *
MUNN ET AL: "Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 18, no. 2, 1 April 2006 (2006-04-01), pages 220 - 225, XP005321333, ISSN: 0952-7915 *
ZHENG XIUFEN ET AL: "Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 OCT 2006, vol. 177, no. 8, 15 October 2006 (2006-10-15), pages 5639 - 5646, XP002481686, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2008068621A2 (fr) 2008-06-12
GB0624308D0 (en) 2007-01-17

Similar Documents

Publication Publication Date Title
WO2008068621A3 (fr) Produit de combinaison
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
WO2008030883A3 (fr) Traitement du cancer
WO2007011962A3 (fr) Traitement du cancer
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
BRPI0509201A (pt) agentes de acoplamento de receptor e usos terapêuticos destes
MX2008000915A (es) Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.
WO2008089397A3 (fr) Marqueurs du cancer adrb2
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
WO2008073899A3 (fr) Compositions associées à prrg4 et procédés d'utilisation de celles-ci dans des procédés de diagnostic de tumeur
WO2008143668A3 (fr) Indoléamine-2, 3-dioxygénase-2
WO2007090194A3 (fr) Codes lymphatiques dans des tumeurs et lesions pre-malignes
WO2008042480A3 (fr) Inhibiteurs époxyde de cystéine protéases
WO2011054837A3 (fr) Promédicaments et médicaments bifonctionnels
WO2008039994A3 (fr) Agent thérapeutique photodynamique ciblé
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
EP1991248A4 (fr) Promédicaments antidépresseurs
AU310232S (en) Impact bracket
WO2008082646A3 (fr) Inhibiteurs de l'histone désacétylase, leurs procédés d'utilisation et polythérapies associées
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
AP2010005435A0 (en) 1,4-Naphthoquinone derivatives and therapeutic usethereof.
AU2010298020A8 (en) Combination
TW200716577A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
WO2007050405A3 (fr) Induction de l'indoleamine 2,3-dioxygenase dans des cellules dendritiques par des ligands tlr et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859330

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07859330

Country of ref document: EP

Kind code of ref document: A2